|
Delaware
(State or other jurisdiction
of incorporation or organization)
|
|
13-3986004
(I.R.S. Employer
Identification No.)
|
|
Part I. Financial Information:
|
PAGE
|
||
ITEM 1. Financial Statements:
|
|||
a.
|
3
|
||
b.
|
4
|
||
c.
|
5
|
||
d.
|
6
|
||
e.
|
7
|
||
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
|
22
|
||
ITEM 3. Quantitative and Qualitative Disclosure about Market Risk
|
29
|
||
ITEM 4. Controls and Procedures
|
29
|
||
Part II. Other Information:
|
|||
ITEM 1. Legal Proceedings
|
29
|
||
ITEM 1A. Risk Factors
|
30
|
||
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds
|
30
|
||
ITEM 3. Defaults Upon Senior Securities
|
30
|
||
ITEM 4. Mine Safety Disclosures
|
30
|
||
ITEM 5. Other Information
|
30
|
||
ITEM 6. Exhibits
|
31
|
||
32
|
|||
E-31.1
|
March 31, 2016
|
December 31, 2015
|
|||||||
ASSETS
|
(unaudited)
|
|||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
3,120
|
$
|
3,303
|
||||
Restricted cash
|
-
|
15
|
||||||
Accounts receivable, net of allowance for doubtful accounts of $80 and $45, respectively
|
3,247
|
4,068
|
||||||
Inventories, net
|
4,152
|
4,128
|
||||||
Prepaid expenses and other current assets
|
377
|
465
|
||||||
Total current assets
|
10,896
|
11,979
|
||||||
Property and equipment, net
|
12,818
|
13,851
|
||||||
Patents and licensed technologies, net
|
7,003
|
7,247
|
||||||
Other intangible assets, net
|
7,770
|
7,980
|
||||||
Goodwill
|
8,928
|
8,928
|
||||||
Other assets
|
94
|
94
|
||||||
Total assets
|
$
|
47,509
|
$
|
50,079
|
||||
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
Current liabilities:
|
||||||||
Note payable
|
$
|
195
|
$
|
299
|
||||
Accounts payable
|
3,503
|
4,446
|
||||||
Other accrued liabilities
|
1,639
|
2,161
|
||||||
Deferred revenues
|
225
|
173
|
||||||
Total current liabilities
|
5,562
|
7,079
|
||||||
Long-term liabilities:
|
||||||||
Long-term debt, net
|
11,344
|
9,851
|
||||||
Senior secured convertible debentures, net
|
10,308
|
9,839
|
||||||
Warrant liability
|
5,057
|
7,042
|
||||||
Deferred tax liability
|
179
|
119
|
||||||
Other liabilities
|
27
|
62
|
||||||
Total liabilities
|
32,477
|
33,992
|
||||||
Commitment and contingencies
|
||||||||
Stockholders' equity:
|
||||||||
Preferred Stock, $.10 par value, 10,000,000 shares authorized; 6,505 shares issued and outstanding
|
1
|
1
|
||||||
Common Stock, $.001 par value, 150,000,000 shares authorized; 10,503,393 and 10,283,393 shares issued and outstanding, respectively
|
11
|
10
|
||||||
Additional paid-in capital
|
223,696
|
223,315
|
||||||
Accumulated deficit
|
(208,677
|
)
|
(207,240
|
)
|
||||
Accumulated other comprehensive income
|
1
|
1
|
||||||
Total stockholders' equity
|
15,032
|
16,087
|
||||||
Total liabilities and stockholders' equity
|
$
|
47,509
|
$
|
50,079
|
For the Three Months Ended
March 31,
|
||||||||
2016
|
2015
|
|||||||
Revenues
|
$
|
7,620
|
$
|
81
|
||||
Cost of revenues
|
3,422
|
711
|
||||||
Gross profit (loss)
|
4,198
|
(630
|
)
|
|||||
|
||||||||
Operating expenses:
|
||||||||
Engineering and product development
|
525
|
239
|
||||||
Selling and marketing
|
3,710
|
1,027
|
||||||
General and administrative
|
2,101
|
1,736
|
||||||
|
6,336
|
3,002
|
||||||
Operating loss before other income (expense), net
|
(2,138
|
)
|
(3,632
|
)
|
||||
|
||||||||
Other income (expense), net:
|
||||||||
Interest expense, net
|
(1,218
|
)
|
(2,324
|
)
|
||||
Change in fair value of warrant liability
|
1,985
|
(1,334
|
)
|
|||||
Other income, net
|
-
|
18
|
||||||
767
|
(3,640
|
)
|
||||||
Loss before income taxes
|
(1,371
|
)
|
(7,272
|
)
|
||||
Income tax expense
|
(66
|
)
|
-
|
|||||
Net loss
|
$ |
(1,437
|
)
|
$ |
(7,272
|
)
|
||
Net loss per share:
|
||||||||
Basic
|
$
|
(0.14
|
)
|
$
|
(1.12
|
)
|
||
Diluted
|
$
|
(0.26
|
)
|
$
|
(1.12
|
)
|
||
Shares used in computing net loss per share:
|
||||||||
Basic
|
10,339,657
|
6,471,906
|
||||||
Diluted
|
13,307,923
|
6,471,906
|
Convertible
Preferred Stock
|
Common Stock
|
Additional
Paid-In
|
Accumulated
|
Accumulated Other Comprehensive
|
||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Deficit
|
Loss
|
Total
|
|||||||||||||||||||||||||
BALANCE, JANUARY 1, 2016
|
6,505
|
$
|
1
|
10,283,393
|
$
|
10
|
$
|
223,315
|
$
|
(207,240
|
)
|
$
|
1
|
$
|
16,087
|
|||||||||||||||||
Stock-based compensation
|
-
|
-
|
-
|
-
|
170
|
-
|
-
|
170
|
||||||||||||||||||||||||
Conversion of senior secured convertible debentures
|
-
|
-
|
220,000
|
1
|
164
|
-
|
-
|
165
|
||||||||||||||||||||||||
Warrants issued in connection with debt
|
-
|
-
|
-
|
-
|
47
|
-
|
-
|
47
|
||||||||||||||||||||||||
Net loss for the three months ended March 31, 2016
|
-
|
-
|
-
|
-
|
-
|
(1,437
|
)
|
-
|
(1,437
|
)
|
||||||||||||||||||||||
BALANCE, MARCH 31, 2016
|
6,505
|
$
|
1
|
10,503,393
|
$
|
11
|
$
|
223,696
|
$
|
(208,677
|
)
|
$
|
1
|
$
|
15,032
|
For the Three Months Ended
March 31,
|
||||||||
2016
|
2015
|
|||||||
Cash Flows From Operating Activities:
|
||||||||
Net loss
|
$
|
(1,437
|
)
|
$
|
(7,272
|
)
|
||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Depreciation and amortization
|
1,684
|
316
|
||||||
Provision for doubtful accounts
|
40
|
1
|
||||||
Stock-based compensation
|
170
|
230
|
||||||
Deferred tax provision
|
60
|
-
|
||||||
Amortization of debt discount
|
639
|
2,015
|
||||||
Amortization of deferred financing costs
|
48
|
180
|
||||||
Change in fair value of warrant liability
|
(1,985
|
)
|
1,334
|
|||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
782
|
214
|
||||||
Inventories
|
(24
|
)
|
113
|
|||||
Prepaid expenses and other assets
|
88
|
(76
|
)
|
|||||
Accounts payable and accrued expenses
|
(955
|
)
|
(110
|
)
|
||||
Other accrued liabilities
|
(523
|
)
|
(8
|
)
|
||||
Other liabilities
|
(35
|
)
|
(10
|
)
|
||||
Deferred revenues
|
52
|
(28
|
)
|
|||||
Net cash used in operating activities
|
(1,396
|
)
|
(3,101
|
)
|
||||
Cash Flows From Investing Activities:
|
||||||||
Lasers placed-in-service, net
|
(197
|
)
|
-
|
|||||
Restricted cash
|
15
|
(100
|
)
|
|||||
Net cash used in investing activities
|
(182
|
)
|
(100
|
)
|
||||
Cash Flows From Financing Activities:
|
||||||||
Proceeds from long-term debt
|
1,500
|
-
|
||||||
Payments on notes payable
|
(105
|
)
|
-
|
|||||
Net cash provided by financing activities
|
1,395
|
-
|
||||||
Net decrease in cash and cash equivalents
|
(183
|
)
|
(3,201
|
)
|
||||
Cash and cash equivalents, beginning of period
|
3,303
|
11,434
|
||||||
Cash and cash equivalents, end of period
|
$
|
3,120
|
$
|
8,233
|
||||
Supplemental information:
|
||||||||
Cash paid for interest
|
$
|
442
|
$
|
139
|
||||
Supplemental information of non-cash investing and financing activities:
|
||||||||
Conversion of senior secured convertible debentures into common stock
|
$
|
165
|
$
|
2,308
|
||||
Conversion of convertible preferred stock into common stock
|
$
|
-
|
$
|
1,508
|
||||
Reclassification of property and equipment to inventory, net
|
$
|
-
|
$
|
26
|
||||
Recognition of warrants issued as debt discount
|
$
|
47
|
$
|
-
|
|
•
|
Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
|
|
•
|
Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
|
|
•
|
Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors
|
Fair Value as of March 31, 2016
|
Quoted Prices in Active Markets for Identical Assets
(Level 1)
|
Significant other Observable Inputs
(Level 2)
|
Significant Unobservable Inputs
(Level 3)
|
|||||||||||||
Liabilities:
|
||||||||||||||||
Warrant liability (Note 10)
|
$
|
5,057
|
$
|
-
|
$
|
-
|
$
|
5,057
|
||||||||
Fair Value as of December 31, 2015
|
Quoted Prices in Active Markets for Identical Assets
(Level 1)
|
Significant other Observable Inputs
(Level 2)
|
Significant Unobservable Inputs
(Level 3)
|
|||||||||||||
Liabilities:
|
||||||||||||||||
Warrant liability (Note 10)
|
$
|
7,042
|
$
|
-
|
$
|
-
|
$
|
7,042
|
March 31, 2016
|
||||
(unaudited)
|
||||
Accrual at beginning of year
|
$
|
226
|
||
Additions charged to warranty expense
|
72
|
|||
Expiring warranties/claimed satisfied
|
(119
|
)
|
||
Total
|
179
|
|||
Less: current portion
|
(155
|
)
|
||
$
|
24
|
March 31, 2016
|
||||
Net loss
|
$
|
(1,437
|
)
|
|
Gain on the change in fair value of the warrant liability
|
(1,985
|
)
|
||
Diluted earnings
|
$
|
(3,422
|
)
|
|
Weighted average number of common and common equivalent shares outstanding:
|
||||
Basic number of common shares outstanding
|
10,339,657
|
|||
Dilutive effect of warrants
|
2,968,266
|
|||
Diluted number of common and common stock equivalent shares outstanding
|
13,307,923
|
March 31,
|
||||||
2016
|
2015
|
|||||
Common stock equivalents of convertible debentures
|
46,215,126
|
4,328,466
|
||||
Common stock purchase warrants
|
16,729,362
|
13,078,920
|
||||
Common stock equivalents of convertible preferred stock
|
2,535,866
|
4,007,406
|
||||
Common stock options
|
2,669,352
|
1,293,701
|
||||
Total
|
68,149,706
|
22,708,493
|
Fair Value
|
||||
Current assets
|
$
|
7,233
|
||
Property, plant and equipment
|
14,340
|
|||
Identifiable intangible assets
|
16,100
|
|||
Other assets
|
45
|
|||
Total assets assumed
|
37,718
|
|||
Current liabilities
|
(3,945
|
)
|
||
Note payable
|
(57
|
)
|
||
Other long term liabilities
|
(116
|
)
|
||
Total liabilities assumed
|
(4,118
|
)
|
||
Net assets acquired
|
$
|
33,600
|
Three Months Ended
March 31,2015
|
||||
(unaudited)
|
||||
Net revenues
|
$
|
7,557
|
||
Net loss
|
$
|
(10,157
|
)
|
|
Net loss per basic and diluted share:
|
$
|
(1.57
|
)
|
|
Shares used in calculating net loss per basic and diluted share:
|
6,471,906
|
March 31, 2016
|
December 31, 2015
|
|||||||
(unaudited)
|
||||||||
Raw materials and work in progress
|
$
|
3,792
|
$
|
3,706
|
||||
Finished goods
|
360
|
422
|
||||||
Total inventories
|
$
|
4,152
|
$
|
4,128
|
March 31, 2016
|
December 31, 2015
|
|||||||
(unaudited)
|
||||||||
Lasers placed-in-service
|
$
|
15,966
|
$
|
15,782
|
||||
Equipment, computer hardware and software
|
1,244
|
1,219
|
||||||
Furniture and fixtures
|
2,054
|
2,080
|
||||||
Leasehold improvements
|
931
|
931
|
||||||
20,195
|
20,012
|
|||||||
Accumulated depreciation and amortization
|
(7,377
|
)
|
(6,161
|
)
|
||||
Property and equipment, net
|
$
|
12,818
|
$
|
13,851
|
March 31, 2016
|
December 31, 2015
|
|||||||
(unaudited)
|
||||||||
Core technology
|
$
|
5,974
|
$
|
5,974
|
||||
Product technology
|
2,000
|
2,000
|
||||||
7,974
|
7,974
|
|||||||
Accumulated amortization
|
(971
|
)
|
(727
|
)
|
||||
Patents and licensed technologies, net
|
$
|
7,003
|
$
|
7,247
|
Remaining 2016
|
$
|
731
|
||
2017
|
975
|
|||
2018
|
975
|
|||
2019
|
975
|
|||
2020
|
775
|
|||
Thereafter
|
2,572
|
|||
Total
|
$
|
7,003
|
March 31, 2016
|
December 31, 2015
|
|||||||
(unaudited)
|
||||||||
Customer relationships
|
$
|
6,900
|
$
|
6,900
|
||||
Tradenames
|
1,500
|
1,500
|
||||||
8,400
|
8,400
|
|||||||
Accumulated amortization
|
(630
|
)
|
(420
|
)
|
||||
Other intangible assets, net
|
$
|
7,770
|
$
|
7,980
|
Remaining 2016
|
$
|
630
|
||
2017
|
840
|
|||
2018
|
840
|
|||
2019
|
840
|
|||
2020
|
840
|
|||
Thereafter
|
3,780
|
|||
Total
|
$
|
7,770
|
March 31, 2016
|
December 31, 2015
|
|||||||
(unaudited)
|
||||||||
Accrued warranty, current, see Note 1
|
$
|
155
|
$
|
168
|
||||
Accrued compensation, including commissions and vacation
|
921
|
1,336
|
||||||
Accrued sales and other taxes
|
375
|
349
|
||||||
Accrued professional fees
|
175
|
265
|
||||||
Other accrued liabilities
|
13
|
43
|
||||||
Total other accrued liabilities
|
$
|
1,639
|
$
|
2,161
|
March 31, 2016
|
December 31, 2015
|
|||||||
(unaudited)
|
||||||||
Senior secured 2.25% convertible debentures, net of unamortized debt discount of $25,718 and $26,267, respectively; and deferred financing costs of $554 and $522, respectively
|
$
|
5,841
|
$
|
5,489
|
||||
Senior secured 4% convertible debentures, net of unamortized debt discount of $3,816 and $3,922, respectively; and deferred financing costs of $432 and $443, respectively
|
4,467
|
4,350
|
||||||
Total convertible debt
|
$
|
10,308
|
$
|
9,839
|
December 31, 2015
|
January 29, 2016
|
|||||||
Number of shares underlying warrants
|
650,442
|
99,057
|
||||||
Exercise price
|
$
|
1.13
|
$
|
1.06
|
||||
Stock price on date of issuance
|
$
|
1.11
|
$
|
1.05
|
||||
Fair value of warrants
|
$
|
321
|
$
|
47
|
||||
Volatility
|
50.0
|
%
|
50.0
|
%
|
||||
Risk-free interest rate
|
1.8
|
%
|
1.8
|
%
|
||||
Expected dividend yield
|
0
|
%
|
0
|
%
|
||||
Expected warrant life
|
5 years
|
5 years
|
March 31, 2016
|
December 31, 2015
|
|||||||
Number of shares underlying the warrants
|
14,099,267
|
14,099,267
|
||||||
Stock price
|
$
|
0.95
|
$
|
1.11
|
||||
Volatility
|
50.00
|
%
|
35.90 – 50.00
|
%
|
||||
Risk-free interest rate
|
0.26% – 1.07
|
%
|
0.02% - 1.63
|
%
|
||||
Expected dividend yield
|
0
|
%
|
0
|
%
|
||||
Expected warrant life
|
0.32 – 4.23 years
|
0.07 – 4.48 years
|
Issuance Date
|
December 31, 2015
|
Decrease in Fair Value
|
March 31, 2016
|
|||||||||
10/31/2013
|
$
|
379
|
$
|
(99
|
)
|
$
|
280
|
|||||
2/5/2014
|
715
|
(187
|
)
|
528
|
||||||||
7/24/2014 Series A (1)
|
2,415
|
(621
|
)
|
1,794
|
||||||||
7/24/2014 Series B (1)
|
1,726
|
(638
|
)
|
1,088
|
||||||||
6/22/2015
|
1,807
|
(440
|
)
|
1,367
|
||||||||
Total
|
$
|
7,042
|
$
|
(1,985
|
)
|
$
|
5,057
|
Issuance Date
|
December 31, 2014
|
Increase in Fair Value
|
March 31, 2015
|
|||||||||
10/31/2013
|
$
|
233
|
$
|
377
|
$
|
610
|
||||||
2/5/2014
|
266
|
957
|
1,223
|
|||||||||
Total
|
$
|
499
|
$
|
1,334
|
$
|
1,833
|
Issuance Date
|
December 31, 2015
|
Additions
|
Reductions
|
March 31, 2016
|
|||
10/31/2013
|
685,715
|
-
|
-
|
685,715
|
|||
2/5/2014
|
1,329,731
|
-
|
-
|
1,329,731
|
|||
7/24/2014 Series A
|
4,288,500
|
-
|
-
|
4,288,500
|
|||
7/24/2014 Series B
|
4,795,321
|
-
|
-
|
4,795,321
|
|||
6/22/2015
|
3,000,000
|
-
|
-
|
3,000,000
|
|||
Total
|
14,099,267
|
-
|
-
|
14,099,267
|
Issue Date
|
Expiration
Date
|
Total
Warrants
|
Exercise
Price
|
||||||
4/26/2013
|
4/26/2018
|
69,321
|
$
|
11.18
|
|||||
10/31/2013
|
4/30/2019
|
685,715
|
$
|
0.75
|
|||||
2/5/2014
|
2/5/2019
|
1,329,731
|
$
|
0.75
|
|||||
7/24/2014
|
7/24/2019
|
6,198,832
|
$
|
0.75 - $ 2.45
|
|||||
7/24/2014
|
7/24/2016
|
4,795,321
|
$
|
0.75
|
|||||
6/22/2015
|
6/22/2020
|
3,000,000
|
$
|
0.75
|
|||||
12/30/2015
|
12/30/2020
|
650,442
|
$
|
1.13
|
|||||
16,729,362
|
Dermatology
Recurring
Procedures
|
Dermatology
Procedures
Equipment
|
Dermatology
Imaging
|
TOTAL
|
|||||||||||||
Revenues
|
$
|
5,528
|
$
|
1,990
|
$
|
102
|
$
|
7,620
|
||||||||
Costs of revenues
|
2,304
|
951
|
167
|
3,422
|
||||||||||||
Gross profit
|
3,224
|
1,039
|
( 65
|
)
|
4,198
|
|||||||||||
Gross profit %
|
58.3
|
%
|
52.2
|
%
|
(63.7
|
%)
|
55.1
|
%
|
||||||||
Allocated operating expenses:
|
||||||||||||||||
Engineering and product development
|
311
|
62
|
152
|
525
|
||||||||||||
Selling and marketing expenses
|
3,510
|
108
|
92
|
3,710
|
||||||||||||
Unallocated operating expenses
|
-
|
-
|
-
|
2,101
|
||||||||||||
3,821
|
170
|
244
|
6,336
|
|||||||||||||
Income (loss) from operations
|
(597
|
)
|
869
|
(309
|
)
|
(2,138
|
)
|
|||||||||
Interest expense, net
|
-
|
-
|
-
|
(1,218
|
)
|
|||||||||||
Change in fair value of warrant liability
|
-
|
-
|
-
|
1,985
|
||||||||||||
Other income (expense), net
|
-
|
-
|
-
|
-
|
||||||||||||
Income (loss) before income taxes
|
$
|
(597
|
)
|
$
|
869
|
$
|
(309
|
)
|
$
|
(1,371
|
)
|
|||||
Dermatology
Recurring
Procedures
|
Dermatology
Procedures
Equipment
|
Dermatology
Imaging
|
TOTAL
|
|||||||||||||
Revenues
|
$
|
-
|
$
|
-
|
$
|
81
|
$
|
81
|
||||||||
Costs of revenues
|
-
|
-
|
711
|
711
|
||||||||||||
Gross profit
|
-
|
-
|
(630
|
)
|
(630
|
)
|
||||||||||
Gross profit %
|
0.0
|
%
|
0.0
|
%
|
(777.8
|
%)
|
(777.8
|
%)
|
||||||||
Allocated operating expenses:
|
||||||||||||||||
Engineering and product development
|
-
|
-
|
239
|
239
|
||||||||||||
Selling and marketing expenses
|
-
|
-
|
1,027
|
1,027
|
||||||||||||
Unallocated operating expenses
|
-
|
-
|
-
|
1,736
|
||||||||||||
-
|
-
|
1,266
|
3,002
|
|||||||||||||
Loss from operations
|
-
|
-
|
(1,896
|
)
|
(3,632
|
)
|
||||||||||
Interest expense, net
|
-
|
-
|
(2,324
|
)
|
||||||||||||
Change in fair value of warrant liability
|
-
|
-
|
-
|
(1,334
|
)
|
|||||||||||
Other income (expense), net
|
-
|
-
|
-
|
18
|
||||||||||||
Net loss
|
$
|
-
|
$
|
-
|
$
|
(1,896
|
)
|
$
|
(7,272
|
)
|
||||||
Three Months Ended
March 31,
|
||||||||
2016
|
2015
|
|||||||
Domestic
|
$
|
5,622
|
$
|
38
|
||||
Foreign
|
1,998
|
43
|
||||||
$
|
7,620
|
$
|
81
|
|||||
•
|
XTRAC® Excimer Laser. XTRAC received FDA clearance in 2000 and has since become a widely recognized treatment among dermatologists for psoriasis and other skin diseases. The XTRAC System delivers ultra-narrowband ultraviolet B ("UVB") light to affected areas of skin. Following a series of treatments typically performed twice weekly, psoriasis remission can be achieved and vitiligo patches can be re-pigmented. XTRAC is endorsed by the National Psoriasis Foundation, and its use for psoriasis is covered by nearly all major insurance companies, including Medicare. We estimate that more than half of all major insurance companies now offer reimbursement for vitiligo as well, a figure that is increasing.
|
|
•
|
VTRAC® Lamp. VTRAC received FDA clearance in 2005 and provides targeted therapeutic efficacy demonstrated by excimer technology with the simplicity of design and reliability of a lamp system.
|
|
•
|
MelaFind®. MelaFind received a Pre-Market Approval, or PMA, from the FDA, in November 2011, having already received in September 2011 Conformité Européenne ("CE") Mark approval. MelaFind is a non-invasive, point–of-care, (i.e. in the doctor's office) instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, (e.g. melanoma). MelaFind aids in the evaluation of clinically atypical pigmented skin lesions, when a dermatologist chooses to obtain additional information before making a final decision to biopsy in order to rule out melanoma. MelaFind acquires and displays multi-spectral (from blue to near infrared) images and dermoscopic Red Green Blue ("RGB") digital data from pigmented skin lesions.
|
For the Three Months Ended
March 31,
|
||||||||
2016
|
2015
|
|||||||
Dermatology Recurring Procedures
|
$
|
5,528
|
$
|
-
|
||||
Dermatology Procedures Equipment
|
1,990
|
-
|
||||||
Dermatology Imaging
|
102
|
81
|
||||||
Total Revenues
|
$
|
7,620
|
$
|
81
|
For the Three Months Ended
March 31,
|
||||||||
2016
|
2015
|
|||||||
Dermatology Recurring Procedures
|
$
|
2,304
|
$
|
-
|
||||
Dermatology Procedures Equipment
|
951
|
-
|
||||||
Dermatology Imaging
|
167
|
711
|
||||||
Total Cost of Revenues
|
$
|
3,422
|
$
|
711
|
For the Three Months Ended March 31, 2016
|
For the Three
|
|||||||||||||||||||
Dermatology Recurring Procedures
|
Dermatology Procedures Equipment
|
Dermatology Imaging
|
Total
|
Months Ended
March 31, 2015
|
||||||||||||||||
Revenues
|
$
|
5,528
|
$
|
1,990
|
$
|
102
|
$
|
7,620
|
$
|
81
|
||||||||||
Cost of revenues
|
2,304
|
951
|
167
|
3,422
|
711
|
|||||||||||||||
Gross profit
|
$
|
3,224
|
$
|
1,039
|
$
|
(65
|
)
|
$
|
4,198
|
$
|
(630
|
)
|
||||||||
Gross margin percentage
|
58.3
|
%
|
52.2
|
%
|
(63.8
|
%)
|
55.1
|
%
|
(777.8
|
%)
|
For the Three Months Ended March 31,
|
||||||||||||
2016
|
2015
|
Change
|
||||||||||
Net loss
|
$
|
(1,437
|
)
|
$
|
(7,272
|
)
|
$
|
5,835
|
||||
Adjustments:
|
||||||||||||
Income taxes
|
66
|
-
|
66
|
|||||||||
Depreciation and amortization
|
1,684
|
316
|
1,368
|
|||||||||
Interest expense, net
|
532
|
139
|
393
|
|||||||||
Non-cash interest expense
|
686
|
2,185
|
(1,499
|
)
|
||||||||
EBITDA
|
1,531
|
(4,632
|
)
|
6,163
|
||||||||
Stock-based compensation expense
|
170
|
230
|
(100
|
)
|
||||||||
Change in fair value of warrants
|
(1,985
|
)
|
1,334
|
(3,319
|
)
|
|||||||
Non-GAAP adjusted EBITDA
|
$
|
(284
|
)
|
$
|
(3,068
|
)
|
$
|
2,784
|
||||
3.1
|
Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Registration Statement on Form S-3 (File No. 333-167113), as filed on May 26, 2010).
|
|
3.2
|
Fourth Amended and Restated Bylaws of the Company (Incorporated by reference to Exhibit 3.2 contained in our Form 8-K current report as filed on July 21, 2015).
|
|
3.3
|
Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2013 filed on August 7, 2014).
|
|
3.4
|
Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, filed on July 10, 2014).
|
|
3.5
|
Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, filed on February 3, 2014).
|
|
3.6
|
Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, filed on July 23, 2014).
|
|
3.7
|
Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, as filed on September 30, 2015).
|
|
31.1
|
Rule 13a-14(a) Certificate of Chief Executive Officer
|
|
31.2
|
Rule 13a-14(a) Certificate of Chief Financial Officer
|
|
32.1*
|
Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
101.INS
|
XBRL Instance Document
|
|
101.SCH
|
XBRL Taxonomy Schema
|
|
101.CAL
|
XBRL Taxonomy Calculation Linkbase
|
|
101.DEF
|
XBRL Taxonomy Definition Linkbase
|
|
101.LAB
|
XBRL Taxonomy Label Linkbase
|
|
101.PRE
|
XBRL Taxonomy Presentation Linkbase
|
*
|
The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed "filed" by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
|
|
STRATA SKIN SCIENCES, INC.
|
|
|
|
|
|
|
Date May 16, 2016
|
By:
|
/s/ Michael R. Stewart
|
|
|
|
Name Michael R. Stewart
|
|
|
|
Title Chief Executive Officer
|
|
Date May 16, 2016
|
By:
|
/s/ Christina L. Allgeier
|
|
|
|
Name Christina L. Allgeier
|
|
|
|
Title Chief Financial Officer
|
|
(1) | I have reviewed this quarterly report on Form 10-Q of STRATA Skin Sciences, Inc.; |
(2) | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
(3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
(4) | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
(5) | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
(a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
(b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Date: May 16, 2016
|
By:
|
/s/ Michael R. Stewart
|
|
|
|
Name: Michael R. Stewart
|
|
|
|
Title: Chief Executive Officer
|
|
(1) | I have reviewed this quarterly report on Form 10-Q of STRATA Skin Sciences, Inc.; |
(2) | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
(3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
(4) | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
(5) | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
(a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
(b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Dated: May 16, 2016
|
By:
|
/s/ Christina Allgeier
|
|
Christina Allgeier
|
|||
Chief Financial Officer
|
|
1.
|
The Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, to which this Certification is attached as Exhibit 32.1 (the "Periodic Report"), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and
|
|
2.
|
The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
|
|
|
|
|
/s/ Michael R. Stewart
|
|
|
|
|
|
Name: Michael R. Stewart
|
|
|
|
|
Title: Chief Executive Officer
|
|
|
|
|
|
|
|
|
/s/ Christina Allgeier
|
|
|
|
|
|
Name: Christina Allgeier
|
|
|
|
|
Title: Chief Financial Officer
|
|
(1)
|
This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of STRATA Skin Sciences, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to STRATA Skin Sciences, Inc. and will be retained by STRATA Skin Sciences, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
|
]:>OS>=>LV>]9UK&SS+QWKOBK(]""LC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1112Z@%,=-PQ3Z*8&->:6LH.17.
M7_A]""=HKNF&:JSVX<'BM(S-(RL>2WF@C>?EKF=3THQ$X6O:9])#DG;6'J'A
MT2Y.W]*VC/4WC4/$+JU=,\&LXQ/GD&O7+[PL,'Y/TKF+_P /F#/RUTQ:9MS'
M)0N4-7X]4:WQ@FH;JU,+'CI5'8STW8&=78^(GR/F-=9IVOL<9:O*H6, ]>U^ +W[1&!G-*
MNM+A66AZ+129I:XCB"BBB@ HHHH **** "BBB@ HHHH **** "N1\??\@23Z
M5UU X4444A!1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-+658WBR@ IUY1\7?^/(4 5OARVZT7->N0?ZI?I7COPW;_
M $5:]AM_]2OTH EHHHH **** "BBB@ HHHH **** &R'"$^U>7>.]2Q;2QJW
M.*]/N#B!_I7@OC6[=M5>(GC- %+P!9M=ZDYD&1NKW"RTB%(A\@KS?X<6B?:-
MPQR:]@C7:M %7^SHO[HIK:9$W515^B@#A/%FBH;5BB
Document and Entity Information - shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
May. 13, 2016 |
|
Document And Entity Information | ||
Entity Registrant Name | STRATA Skin Sciences, Inc. | |
Entity Central Index Key | 0001051514 | |
Current Fiscal Year End Date | --12-31 | |
Entity Well-known Seasoned Issuer | No | |
Entity Voluntary Filers | No | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 10,587,804 | |
Document Fiscal Year Focus | 2016 | |
Document Fiscal Period Focus | Q1 | |
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 31, 2016 |
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands |
Mar. 31, 2016 |
Dec. 31, 2015 |
---|---|---|
Current assets: | ||
Allowance for doubtful accounts, current | $ 80 | $ 45 |
Stockholders' equity: | ||
Preferred stock, par value (in dollars per share) | $ 0.10 | $ 0.10 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares issued (in shares) | 6,505 | 6,505 |
Preferred stock, shares outstanding (in shares) | 6,505 | 6,505 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 150,000,000 | 150,000,000 |
Common stock, shares issued (in shares) | 10,503,393 | 10,283,393 |
Common stock, shares outstanding (in shares) | 10,503,393 | 10,283,393 |
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited) - 3 months ended Mar. 31, 2016 - USD ($) $ in Thousands |
Convertible Preferred Stock [Member] |
Common Stock [Member] |
Additional Paid-In Capital [Member] |
Accumulated Deficit [Member] |
Accumulated Other Comprehensive Loss [Member] |
Total |
---|---|---|---|---|---|---|
Beginning balance at Dec. 31, 2015 | $ 1 | $ 10 | $ 223,315 | $ (207,240) | $ 1 | $ 16,087 |
Beginning balance (in shares) at Dec. 31, 2015 | 6,505 | 10,283,393 | ||||
Stock-based compensation | $ 0 | $ 0 | 170 | 0 | 0 | 170 |
Conversion of senior secured convertible debentures | $ 0 | $ 1 | 164 | 0 | 0 | 165 |
Conversion of senior secured convertible debentures (in shares) | 0 | 220,000 | ||||
Warrants issued in connection with debt | $ 0 | $ 0 | 47 | 0 | 0 | 47 |
Net loss for the three months ended March 31, 2016 | 0 | 0 | 0 | (1,437) | 0 | (1,437) |
Ending balance at Mar. 31, 2016 | $ 1 | $ 11 | $ 223,696 | $ (208,677) | $ 1 | $ 15,032 |
Ending balance (in shares) at Mar. 31, 2016 | 6,505 | 10,503,393 |
The Company |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Company [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Company | Note 1 The Company: Background STRATA Skin Sciences, Inc. (and its subsidiary) ("STRATA" or "we" or the "Company") is a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders. In June 2015 the Company completed the acquisition of the XTRAC Excimer Laser and the VTRAC excimer lamp businesses from PhotoMedex, Inc. which included a subsidiary in India, PhotoMedex India Ltd. The XTRAC® and VTRAC® products are FDA cleared devices for the treatment of psoriasis, vitiligo and other skin disorders. The purchase price was $42,500 plus the assumption of certain business-related liabilities. Management believes that the cash flow generated by these businesses will be sufficient to finance the Company's operations for the foreseeable future. (See Note 2, Acquisition.) The XTRAC is an ultraviolet light excimer laser system utilized to treat psoriasis, vitiligo and other skin diseases. The XTRAC received FDA clearance in 2000 and has since become a recognized treatment among dermatologists. The system delivers targeted 308um ultraviolet light to affected areas of the skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. As of March 31, 2016, there were 730 XTRAC systems placed in dermatologists' offices in the United States under the Company's recurring revenue business model. The XTRAC systems employed under the recurring revenue model generate revenue on a per procedure basis. The per-procedure charge is inclusive of the use of the system and the services provided by the Company to the customer which includes system maintenance, reimbursement support service and participation in the direct to patient marketing programs employed by the Company. The XTRAC system's use for psoriasis is covered by nearly all major insurance companies, including Medicare. The VTRAC Excimer Lamp system, offered in addition to the XTRAC system internationally, provides targeted therapeutic efficacy demonstrated by excimer technology with the simplicity of design and reliability of a lamp system. Liquidity As of March 31, 2016, the Company had an accumulated deficit of $208,677 and has incurred losses and negative cash flows from operations since inception. To date, the Company has dedicated most of its financial resources to research and development, sales and marketing, and general and administrative expenses. The Company has been dependent on raising capital from the sale of securities in order to continue to operate and to meet its obligations in the ordinary course of business. Management believes that its cash and cash equivalents as of March 31, 2016 combined with the anticipated revenues from the sale of the Company's products will be sufficient to satisfy its working capital needs, capital asset purchases, outstanding commitments and other liquidity requirements associated with its existing operations through the second quarter of 2017. Basis of Presentation: Accounting Principles The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. Quarterly Financial Information and Results of Operations The condensed consolidated financial statements as of March 31, 2016 and for the three months ended March 31, 2016 and 2015 are unaudited and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial position as of March 31, 2016, the results of operations for the three months ended March 31, 2016 and 2015, the statement of stockholders' equity for the three months ended March 31, 2016 and the statement of cash flows for the three months ended March 31, 2016 and 2015. The results of operations and cash flows for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the entire year. The condensed consolidated balance sheet as of December 31, 2015 was derived from audited financial statements as of December 31, 2015. While management of the Company believes that the disclosures presented are adequate to make the information not misleading, these condensed consolidated financial statements should be read in conjunction with audited consolidated financial statements and the footnotes thereto, together with Management's Discussion and Analysis of Financial Condition and Results of Operations, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015. Reclassification Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have a material impact on the Company's equity, net assets, results of operations or cash flows. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the US requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of March 31, 2016, the more significant estimates include (1) revenue recognition, including deferred revenues and valuation allowances of accounts receivable, (2) the fair value of assets acquired and liabilities assumed in the business combination, (3) the estimated useful lives of intangible assets and property and equipment, (4) the inputs used in determining the fair value of equity-based awards and (5) the valuation allowance related to deferred tax assets. Fair Value Measurements The Company measures and discloses fair value in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification 820, Fair Value Measurements and Disclosures ("ASC Topic 820"). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's recurring fair value measurements at March 31, 2016 and December 31, 2015 are as follows:
The fair value of cash and cash equivalents are based on their respective demand value, which are equal to the carrying value. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of the Company's warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures. The carrying value of all other short-term monetary assets and liabilities is estimated to be approximate to their fair value due to the short-term nature of these instruments. The Company assessed its convertible debentures and long-term debt and determined that the fair value of total debt was $18,251 as of March 31, 2016. As of December 31, 2015 the fair value of total debt approximated the recorded value of $15,958. Several of the warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon change in control of the Company and other warrants contain full ratchet provisions that reduce the exercise price of the warrants in the event of a transaction resulting in the issuance of equity below the current price of the warrants. Therefore these warrants are classified as derivatives. These warrants have been recorded at their fair value using a binomial option pricing model and will be recorded at their respective fair value at each subsequent balance sheet date. See Note 10, Warrants, for additional discussion. Accrued Warranty Costs The Company offers a standard warranty on product sales generally for a one to two-year period The Company provides for the estimated cost of the future warranty claims on the date the product is sold. Total accrued warranty is included in Other Accrued Liabilities and Other liabilities on the balance sheet. The activity in the warranty accrual during the three months ended March 31, 2016 is summarized as follows:
Earnings Per Share Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period and their potential diluted effect is considered using the treasury method. For the three months ended March 31, 2016 diluted earnings per common share are computed by the numerator effected by the gain on the change in fair value of the warrant liability and the denominator is increased to include the number of additional potential common shares from the warrants underlying the warrant liability. Diluted earnings per common share were calculated using the following net loss and weighted average shares outstanding for the three months ended March 31, 2016:
For the three months ended March 31, 2015, diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive. The loss on the change in fair value of the warrant liability would be considered in the diluted earnings per share calculation and was deemed to be antidilutive. Potential common stock equivalents outstanding as of March 31, 2016 and 2015 consist of common stock equivalents of common stock purchase warrants, senior secured convertible debentures, convertible preferred stock and common stock options, which are summarized as follows:
Adoption of New Accounting Standards In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs" (Subtopic 835-30). ASU No. 2015-03 provides guidance that will require debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, in the same manner as debt discounts, rather than as an asset. The standard was effective for reporting periods beginning after December 15, 2015 and early adoption was permitted. The Company adopted this ASU effective January 1, 2016. (See Note 8, Convertible Debentures.) In September 2015, the FASB issued ASU No. 2015-16, "Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments." The amendments in ASU 2015-16 require that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined, rather than retrospectively adjusting amounts previously reported. The amendments require that the acquirer record, in the same period's financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. Effective for public business entities for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The amendments should be applied prospectively to adjustments to provisional amounts that occur after the effective date with earlier application permitted for financial statements that have not been issued. The adoption of this ASU did not have a significant impact on the condensed consolidated financial statements. Recently Issued Accounting Standards In February 2016, the FASB issued ASU 2016-02, Leases, This statement requires lessees to present right-of-use assets and lease liabilities on the balance sheet. The standard is effective for public companies for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the effect the guidance will have on its financial condition and results of operations. In November 2015, the FASB issued ASU 2015-17, Income Taxes, Balance Sheet Classification of Deferred Taxes topic of the Codification. This standard requires all deferred tax assets and liabilities to be classified as non-current on the balance sheet instead of separating deferred taxes into current and non-current amounts. In addition, valuation allowance allocations between current and non-current deferred tax assets are no longer required because those allowances also will be classified as non-current. This standard is effective for public companies for annual periods beginning after December 15, 2016 and March 31, 2016. The Company's deferred tax assets is provided with full valuation allowance as of December 31, 2015. As such, the Company does not expect that this standard will have a significant impact on its consolidated financial statements and disclosures upon adoption. In July, 2015, The FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11"). ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out (LIFO) are not impacted by the new guidance. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early adoption is permitted as of the beginning of an interim or annual reporting period. The Company is in the process of assessing the impact, if any, of ASU 2015-11 on its consolidated financial statements. In May 2014, The FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"). ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures. For a public entity, the amendments in ASU 2014-09 were to be effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In July 2015, the FASB voted for a one year deferral of the effective date of ASU 2014-09 and issued an exposure draft. The new guidance will be effective for annual and interim periods beginning on or after December 15, 2017. Early application is not permitted. The Company is currently assessing the impact that adopting this new accounting guidance will have on its consolidated financial statements and footnote disclosures. In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). ASU 2014-15 provides guidance on management's responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 also provides guidance related to the required disclosures as a result of management evaluation. The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the new guidance to determine the impact the adoption of this guidance will have on the Company's results of operations, cash flows or financial condition. |
Acquisition |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisition [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisition | Note 2 Acquisition: On June 22, 2015, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") with PhotoMedex Inc. and PhotoMedex Technology, Inc. pursuant to which the Company has purchased the XTRAC and VTRAC laser businesses from PhotoMedex, Inc. (the "Asset Purchase") for $42,528 in cash and assumed certain business-related liabilities. The purchased assets include all of the accounts receivable, inventory and fixed and intangible assets of the business. The fair value of the assets acquired and liabilities assumed were based on management. The significant intangible assets to be recognized in the valuation are core and product technologies, tradenames and customer relationships. The estimated useful lives over which these assets will be amortized, utilizing the straight line method, are five years for product technologies and ten years for core technologies, tradenames and customer relationships. The following allocation of the aggregate fair value is subject to adjustment based on the fair value of the assets acquired and the liabilities assumed. The Company estimated fair value of the intangibles and lasers placed in service was based on the income approach which estimated cash flow that utilize appropriate discount and capitalization rates and available market information. Estimates of future cash flows are based on a number of factors including the historical operating results, known trends and specific market and economic conditions. The fair value of the Company's remaining fixed assets was estimated based on the cost approach which estimated the cost to replace.
The purchase price exceeded the fair value of the net assets acquired by $8,928, which was recorded as goodwill. The consolidated results of operations do not include any revenues or expenses related to XTRAC and VTRAC businesses on or prior to June 22, 2015, the date of the asset purchase. The Company's unaudited pro-forma results for the three months ended March 31, 2015 summarize the combined results in the following table, assuming the asset purchase had occurred on January 1, 2015 and after giving effect to the acquisition adjustments, including amortization of the tangible and long-lived intangible assets acquired in the transaction:
These unaudited pro-forma results have been prepared for comparative purposes only and do not purport to be indicative of the results of operations which would have actually resulted had the acquisition occurred on January 1, 2014, nor to be indicative of future results of operations. |
Inventories, net |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||
Inventories, net [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
Inventories, net | Note 3 Inventories, net:
Work-in-process is immaterial, given the Company's typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials. |
Property and Equipment, net |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property and Equipment, net [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property and Equipment, net | Note 4 Property and Equipment, net:
Depreciation and related amortization expense was $1,230 and $41 for the three months ended March 31, 2016 and 2015, respectively. Note 5 |
Patents and Licensed Technologies, net |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Patents and Licensed Technologies, net [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Patents and Licensed Technologies, net | Note 5 Patents and Licensed Technologies, net:
Related amortization expense was $244 and $1 for each of the three month ended March 31, 2016 and 2015. Estimated amortization expense for amortizable patents and licensed technologies assets for the future periods is as follows:
|
Other Intangible Assets |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Intangible Assets [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Intangible Assets | Note 6 Other Intangible Assets: Set forth below is a detailed listing of other definite-lived intangible assets:
Related amortization expense was $210 and $ 0 for the three months ended March 31, 2016 and 2015, respectively. Estimated amortization expense for the above amortizable intangible assets for the future periods is as follows:
|
Other Accrued Liabilities |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Accrued Liabilities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Accrued Liabilities | Note 7 Other Accrued Liabilities:
|
Convertible Debentures |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debentures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debentures | Note 8 Convertible Debentures: In the following table is a summary of the Company's convertible debentures.
The Company issued $32,500 aggregate principal amount of Debentures (June 2015 Debentures) that, subject to certain ownership limitations and stockholder approval conditions, will be convertible into 43,333,334 shares of Company common stock at an initial conversion price of $0.75 per share. The Debentures bear interest at the rate of 2.25% per year, and, unless previously converted, will mature on the five-year anniversary of the date of issuance, June 22, 2020. The June 2015 Debentures include a beneficial conversion feature valued at $27,300 that was recorded as a discount to the debentures. On the date of issuance the beneficial conversion feature value was calculated as the difference resulting from subtracting the conversion price of $0.75 from $1.38, the opening market value of the Company's common stock following the announcement of the transaction, multiplied by the number of common shares into which the June 2015 Debentures are convertible. This discount is being amortized over the five year life of the June 2015 Debentures using the effective interest method. The embedded conversion feature contains an anti-dilution provision that allows for downward exercise price adjustments in certain situations. The embedded conversion feature was not bifurcated as it did not meet all of the elements of a derivative. On July 21, 2014, the Company entered into a definitive Securities Purchase Agreement (the "Purchase Agreement") with institutional investors (the "Investors") providing for the issuance of Senior Secured Convertible Debentures in the aggregate principal amount of $15,000, due, subject to the terms therein, in July 2019 (the "July 2014 Debentures"), and warrants (the "July 2014 Series A Warrants") to purchase up to an aggregate of 6,198,832 shares of common stock, $0.001 par value per share, at an exercise price of $2.45 per share expiring in July 2019. The July 2014 Debentures bear interest at an annual rate of 4%, payable quarterly or upon conversion into shares of common stock. The Debentures are convertible at any time into an aggregate of 5,847,955 shares of common stock at an initial conversion price of $2.565 per share. The Company's obligations under the July 2014 Debentures are secured by a first priority lien on all of the Company's intellectual property pursuant to the terms of a security agreement ("Security Agreement") dated July 21, 2014 among the Company and the Investors. In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement with the Investors pursuant to which the Company was obligated to file a registration statement to register for resale the shares of Common Stock issuable upon conversion of the Series B Preferred Stock (See Note 10, Warrants) and Debentures and upon exercise of the Warrants. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on August 19, 2014, which was declared effective by the SEC on October 20, 2014 (File No. 333-198249). For financial reporting purposes, the $15,000 funded by the Investors on July 21, 2014 was allocated first to the fair value of the obligation to issue the Warrants, amounting to $5,296, then to the intrinsic value of the beneficial conversion feature on the July 2014 Debentures of $4,565. The balance was further reduced by the fair value of warrants issued to the placement agent for services rendered of $491, resulting in an initial carrying value of the Debentures of $4,647. The initial debt discount on the July 2014 Debentures totaled $10,353 and is being amortized using the effective interest method over the five year life of the July 2014 Debentures. During the three months ended March 31, 2016, the investors converted debentures amounting to $165 into 220,000 shares of common stock for the June 2015 note. The debt discount and deferred financing cost adjustment resulting from the conversions increased interest expense by $136 for the three months ended March 31, 2016. As a condition of the new note facility (See Note 9, Long-term Debt) the Debentures from both the 2014 and 2015 financings were amended. The Debentures holders' first priority lien was subordinated to the new term note facility. Additionally, as a condition of the term note facility, the maturity date of both Debentures was extended to June 30, 2021. The Company evaluated the modifications to determine if there was an extinguishment of debt. Based on the valuation, the discounted cash flows did not change by more than 10%, thus they were treated as a modification. As of March 31, 2016, the total outstanding amount of Debentures was $40,828. |
Long-term Debt |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | Note 9 Long-term Debt: Term-Note Credit Facility On December 30, 2015, the Company entered into a $12,000 credit facility pursuant to a Credit and Security Agreement (the "Agreement") and related financing documents with MidCap Financial Trust ("MidCap") and the lenders listed therein. Under the Agreement, the credit facility may be drawn down in two tranches, the first of which was drawn for $10,500 on December 30, 2015. The proceeds of this first tranche were used to repay $10,000 principal amount of short-term senior secured promissory notes, plus associated interest, loan fees and expenses. The second tranche was drawn for $1,500 on January 29, 2016. The Company's obligations under the credit facility are secured by a first priority lien on all of the Company's assets. This credit facility includes both financial and non-financial covenants, including a minimum net revenue covenant, beginning in January 2016. The Company is in compliance with these covenants as of March 31, 2016. Interest rate on the credit facility is one month LIBOR plus 8.25%, subject to a LIBOR floor of 0.5%. The Company's existing debentures from its 2014 and 2015 financings were amended as a condition of this new term note facility, including subordination agreements and maturity extensions. As of March 31, 2016 the net balance of long-term debt is $11,344. In connection with the issuance of the Term Note the Company issued MidCap (and the lenders), on December 30, 2015, a warrant to purchase 650,442 shares of the Company's common stock for an exercise price of $1.13. Additionally, the Company issued MidCap (and the lenders), on January 29, 2016, a warrant to purchase 99,057 shares of the Company's common stock for an exercise price of $1.06. The warrants are exercisable at any time on or prior to the fifth anniversary of its issue date. The warrants are treated as a discount to the debt and are accreted under the effective interest method over the repayment term of 60 months. The Company has accounted for these warrants as equity instruments since there is no option for cash or net-cash settlement when the warrants are exercised and since they are indexed to the Company's common stock. The Company computed the value of the warrants using the Black-Scholes method. The key assumptions used to value the warrants are as follows:
|
Warrants |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants | Note 10 Warrants: The Company accounts for warrants that have provisions that protect holders from a decline in the issue price of its common stock (or "down-round" provisions) as liabilities instead of equity. Down-round provisions reduce the exercise or conversion price of a warrant or convertible instrument if a company either issues equity shares for a price that is lower than the exercise or conversion price of those instruments or issues new warrants or convertible instruments that have a lower exercise or conversion price. Net settlement provisions allow the holder of the warrant to surrender shares underlying the warrant equal to the exercise price as payment of its exercise price, instead of physically exercising the warrant by paying cash. The Company evaluated whether warrants to acquire its common stock contain provisions that protect holders from declines in the stock price or otherwise could result in modification of the exercise price and/or shares to be issued under the respective warrant agreements based on a variable that is not an input to the fair value of a "fixed-for-fixed" option. The Company recognizes such warrants as liabilities at the fair value on each reporting date. The Company computed the value of the warrants using the binomial method. A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company's warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of March 31, 2016 and December 31, 2015 is as follows:
Recurring Level 3 Activity and Reconciliation The tables below provide a reconciliation of the beginning and ending balances for the liability measured at fair value using significant unobservable inputs (Level 3). The table reflects gains and losses for the three month periods ended March 31, 2016 and 2015, for all financial liabilities categorized as Level 3 as of March 31, 2016 and March 31, 2015, respectively. Fair Value Measurements Using Significant Unobservable Inputs (Level 3):
(1) These warrants were modified on September 30, 2015 and as a result of the modification these warrants met the definition of a derivative and were reclassified to a warrant liability.
Number of Warrants Subject to Remeasurement:
|
Stockholders' Equity |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity | Note 11 Stockholders' Equity: Common Stock and Warrants Outstanding common stock warrants consist at March 31, 2016 of the following:
|
Stock-based compensation |
3 Months Ended |
---|---|
Mar. 31, 2016 | |
Stock-based compensation [Abstract] | |
Stock-based compensation | Note 12 Stock-based compensation: At March 31, 2016, the Company had 2,614,600 options outstanding with a weighted-average exercise price of $1.51. 1,664,600 options are vested and exercisable. Stock-based compensation expense, primarily included in general and administration, for the three months ended March 31, 2016 and 2015 was $170 and $230, respectively. As of March 31, 2016 there was $488 in unrecognized compensation expense, which will be recognized over a weighted average period of 1.15 years. |
Income taxes |
3 Months Ended |
---|---|
Mar. 31, 2016 | |
Income taxes [Abstract] | |
Income taxes | Note 13 Income taxes: The Company accounts for income taxes using the asset and liability method for deferred income taxes. The provision for income taxes includes federal, state and local income taxes currently payable and deferred taxes resulting from temporary differences between the financial statement and tax bases of assets and liabilities. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Income tax expense of $66 for the three months ended March 31, 2016 was comprised of the change in deferred tax liability related to goodwill. Goodwill is an amortizing asset according to tax regulations. This generates a deferred tax liability that is not used to offset deferred tax assets for valuation allowance considerations. There was no such expense for the three months ended March 31, 2015. |
Business Segments and Geographic Data |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Segments and Geographic Data [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Segments and Geographic Data | Note 14 Business Segments and Geographic Data: The Company organized its business into three operating segments to better align its organization based upon the Company's management structure, products and services offered, markets served and types of customers, as follows: The Dermatology Recurring Procedures segment derives its revenues from the XTRAC procedures performed by dermatologists. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The Dermatology Imaging segment generates revenues from the sale and usage of imaging devices. Management reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance. On June 22, 2015, the Company acquired the XTRAC and VTRAC businesses and has classified the revenues and expenses of this business to the two Dermatology Procedures segments. There are no corresponding revenues for the three months ended March 31, 2015. Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other financing income (expense), net is also not allocated to the operating segments. The following tables reflect results of operations from our business segments for the periods indicated below: Three Months Ended March 31, 2016 (unaudited)
Three Months Ended March 31, 2015 (unaudited)
For the three months ended March 31, 2016 and 2015 there were no material net revenues attributable to any individual foreign country. Net revenues by geographic area were, as follows:
|
Significant Customer Concentration |
3 Months Ended |
---|---|
Mar. 31, 2016 | |
Significant Customer Concentration [Abstract] | |
Significant Customer Concentration | Note 15 Significant Customer Concentration: For the three months ended March 31, 2016, revenues from sales to the Company's international master distributor (GlobalMed Technologies) were $1,686, or 22.1%, of total revenues for such period. At March 31, 2016, the accounts receivable balance from GlobalMed Technologies was $443, or 13.6%, of total net accounts receivable. No other customer represented more than 10% of total company revenues for the three months ended March 31, 2016 and 2015. |
Subsequent Events |
3 Months Ended |
---|---|
Mar. 31, 2016 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 16 Subsequent Events: On April 5, 2016, investors converted debentures amounting to $63 into 84,411 shares of common stock. See Note 8, Convertible Debentures. |
The Company (Policies) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Company [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Liquidity | Liquidity As of March 31, 2016, the Company had an accumulated deficit of $208,677 and has incurred losses and negative cash flows from operations since inception. To date, the Company has dedicated most of its financial resources to research and development, sales and marketing, and general and administrative expenses. The Company has been dependent on raising capital from the sale of securities in order to continue to operate and to meet its obligations in the ordinary course of business. Management believes that its cash and cash equivalents as of March 31, 2016 combined with the anticipated revenues from the sale of the Company's products will be sufficient to satisfy its working capital needs, capital asset purchases, outstanding commitments and other liquidity requirements associated with its existing operations through the second quarter of 2017. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Principles | Accounting Principles The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principles of Consolidation | Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quarterly Financial Information and Results of Operations | Quarterly Financial Information and Results of Operations The condensed consolidated financial statements as of March 31, 2016 and for the three months ended March 31, 2016 and 2015 are unaudited and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial position as of March 31, 2016, the results of operations for the three months ended March 31, 2016 and 2015, the statement of stockholders' equity for the three months ended March 31, 2016 and the statement of cash flows for the three months ended March 31, 2016 and 2015. The results of operations and cash flows for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the entire year. The condensed consolidated balance sheet as of December 31, 2015 was derived from audited financial statements as of December 31, 2015. While management of the Company believes that the disclosures presented are adequate to make the information not misleading, these condensed consolidated financial statements should be read in conjunction with audited consolidated financial statements and the footnotes thereto, together with Management's Discussion and Analysis of Financial Condition and Results of Operations, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reclassification | Reclassification Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have a material impact on the Company's equity, net assets, results of operations or cash flows. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Use of Estimates | Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the US requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of March 31, 2016, the more significant estimates include (1) revenue recognition, including deferred revenues and valuation allowances of accounts receivable, (2) the fair value of assets acquired and liabilities assumed in the business combination, (3) the estimated useful lives of intangible assets and property and equipment, (4) the inputs used in determining the fair value of equity-based awards and (5) the valuation allowance related to deferred tax assets. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | Fair Value Measurements The Company measures and discloses fair value in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification 820, Fair Value Measurements and Disclosures ("ASC Topic 820"). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's recurring fair value measurements at March 31, 2016 and December 31, 2015 are as follows:
The fair value of cash and cash equivalents are based on their respective demand value, which are equal to the carrying value. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of the Company's warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures. The carrying value of all other short-term monetary assets and liabilities is estimated to be approximate to their fair value due to the short-term nature of these instruments. The Company assessed its convertible debentures and long-term debt and determined that the fair value of total debt was $18,251 as of March 31, 2016. As of December 31, 2015 the fair value of total debt approximated the recorded value of $15,958. Several of the warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon change in control of the Company and other warrants contain full ratchet provisions that reduce the exercise price of the warrants in the event of a transaction resulting in the issuance of equity below the current price of the warrants. Therefore these warrants are classified as derivatives. These warrants have been recorded at their fair value using a binomial option pricing model and will be recorded at their respective fair value at each subsequent balance sheet date. See Note 10, Warrants, for additional discussion. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Warranty Costs | Accrued Warranty Costs The Company offers a standard warranty on product sales generally for a one to two-year period The Company provides for the estimated cost of the future warranty claims on the date the product is sold. Total accrued warranty is included in Other Accrued Liabilities and Other liabilities on the balance sheet. The activity in the warranty accrual during the three months ended March 31, 2016 is summarized as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share | Earnings Per Share Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period and their potential diluted effect is considered using the treasury method. For the three months ended March 31, 2016 diluted earnings per common share are computed by the numerator effected by the gain on the change in fair value of the warrant liability and the denominator is increased to include the number of additional potential common shares from the warrants underlying the warrant liability. Diluted earnings per common share were calculated using the following net loss and weighted average shares outstanding for the three months ended March 31, 2016:
For the three months ended March 31, 2015, diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive. The loss on the change in fair value of the warrant liability would be considered in the diluted earnings per share calculation and was deemed to be antidilutive. Potential common stock equivalents outstanding as of March 31, 2016 and 2015 consist of common stock equivalents of common stock purchase warrants, senior secured convertible debentures, convertible preferred stock and common stock options, which are summarized as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adoption of New Accounting Standards | Adoption of New Accounting Standards In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs" (Subtopic 835-30). ASU No. 2015-03 provides guidance that will require debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, in the same manner as debt discounts, rather than as an asset. The standard was effective for reporting periods beginning after December 15, 2015 and early adoption was permitted. The Company adopted this ASU effective January 1, 2016. (See Note 8, Convertible Debentures.) In September 2015, the FASB issued ASU No. 2015-16, "Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments." The amendments in ASU 2015-16 require that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined, rather than retrospectively adjusting amounts previously reported. The amendments require that the acquirer record, in the same period's financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. Effective for public business entities for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The amendments should be applied prospectively to adjustments to provisional amounts that occur after the effective date with earlier application permitted for financial statements that have not been issued. The adoption of this ASU did not have a significant impact on the condensed consolidated financial statements. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recently Issued Accounting Standards | Recently Issued Accounting Standards In February 2016, the FASB issued ASU 2016-02, Leases, This statement requires lessees to present right-of-use assets and lease liabilities on the balance sheet. The standard is effective for public companies for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the effect the guidance will have on its financial condition and results of operations. In November 2015, the FASB issued ASU 2015-17, Income Taxes, Balance Sheet Classification of Deferred Taxes topic of the Codification. This standard requires all deferred tax assets and liabilities to be classified as non-current on the balance sheet instead of separating deferred taxes into current and non-current amounts. In addition, valuation allowance allocations between current and non-current deferred tax assets are no longer required because those allowances also will be classified as non-current. This standard is effective for public companies for annual periods beginning after December 15, 2016 and March 31, 2016. The Company's deferred tax assets is provided with full valuation allowance as of December 31, 2015. As such, the Company does not expect that this standard will have a significant impact on its consolidated financial statements and disclosures upon adoption. In July, 2015, The FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11"). ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out (LIFO) are not impacted by the new guidance. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early adoption is permitted as of the beginning of an interim or annual reporting period. The Company is in the process of assessing the impact, if any, of ASU 2015-11 on its consolidated financial statements. In May 2014, The FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"). ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures. For a public entity, the amendments in ASU 2014-09 were to be effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In July 2015, the FASB voted for a one year deferral of the effective date of ASU 2014-09 and issued an exposure draft. The new guidance will be effective for annual and interim periods beginning on or after December 15, 2017. Early application is not permitted. The Company is currently assessing the impact that adopting this new accounting guidance will have on its consolidated financial statements and footnote disclosures. In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). ASU 2014-15 provides guidance on management's responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 also provides guidance related to the required disclosures as a result of management evaluation. The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the new guidance to determine the impact the adoption of this guidance will have on the Company's results of operations, cash flows or financial condition. |
The Company (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Company [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements on Recurring Basis | The Company's recurring fair value measurements at March 31, 2016 and December 31, 2015 are as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Warranty Costs Activity | The activity in the warranty accrual during the three months ended March 31, 2016 is summarized as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diluted Earnings Per Common Share Calculated using Net Loss And Weighted Average Shares Outstanding | Diluted earnings per common share were calculated using the following net loss and weighted average shares outstanding for the three months ended March 31, 2016:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | Potential common stock equivalents outstanding as of March 31, 2016 and 2015 consist of common stock equivalents of common stock purchase warrants, senior secured convertible debentures, convertible preferred stock and common stock options, which are summarized as follows:
|
Acquisition (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisition [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Estimated Fair Value of Assets Acquired and Liabilities Assumed | The fair value of the Company's remaining fixed assets was estimated based on the cost approach which estimated the cost to replace.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unaudited Pro-forma Results | The Company's unaudited pro-forma results for the three months ended March 31, 2015 summarize the combined results in the following table, assuming the asset purchase had occurred on January 1, 2015 and after giving effect to the acquisition adjustments, including amortization of the tangible and long-lived intangible assets acquired in the transaction:
|
Inventories, net (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||
Inventories, net [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Inventory | Inventories, net:
|
Property and Equipment, net (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property and Equipment, net [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Property and Equipment, Net | Property and Equipment, net:
|
Patents and Licensed Technologies, net (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Patents and Licensed Technologies, net [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Patents and Licensed Technologies, Net | Patents and Licensed Technologies, net:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Estimated Amortization Expense for Amortizable Patents and Licensed Technologies Assets | Estimated amortization expense for amortizable patents and licensed technologies assets for the future periods is as follows:
|
Other Intangible Assets (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Intangible Assets [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Other Definite-lived Intangible Assets | Set forth below is a detailed listing of other definite-lived intangible assets:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Finite-lived Intangible Assets Amortization Expense | Estimated amortization expense for the above amortizable intangible assets for the future periods is as follows:
|
Other Accrued Liabilities (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Accrued Liabilities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Other Accrued Liabilities | Other Accrued Liabilities:
|
Convertible Debentures (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debentures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
Summary of Convertible Debentures | In the following table is a summary of the Company's convertible debentures.
|
Long-term Debt (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key Assumptions Used to Value the Warrants under Long-term Debt | The key assumptions used to value the warrants are as follows:
|
Warrants (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants Fair Value Assumptions | A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company's warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of March 31, 2016 and December 31, 2015 is as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Derivative Warrant Liabilities | Fair Value Measurements Using Significant Unobservable Inputs (Level 3):
(1) These warrants were modified on September 30, 2015 and as a result of the modification these warrants met the definition of a derivative and were reclassified to a warrant liability.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Warrants Subject to Remeasurement | Number of Warrants Subject to Remeasurement:
|
Stockholders' Equity (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Outstanding Common Stock Warrants | Outstanding common stock warrants consist at March 31, 2016 of the following:
|
Business Segments and Geographic Data (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Segments and Geographic Data [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Segment Reporting Information by Segment | The following tables reflect results of operations from our business segments for the periods indicated below: Three Months Ended March 31, 2016 (unaudited)
Three Months Ended March 31, 2015 (unaudited)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Net Revenues by Geographic Areas | For the three months ended March 31, 2016 and 2015 there were no material net revenues attributable to any individual foreign country. Net revenues by geographic area were, as follows:
|
Inventories, net (Details) - USD ($) $ in Thousands |
Mar. 31, 2016 |
Mar. 31, 2015 |
---|---|---|
Schedule of inventory [Abstract] | ||
Raw materials and work in progress | $ 3,792 | $ 3,706 |
Finished goods | 360 | 422 |
Total inventories | $ 4,152 | $ 4,128 |
Property and Equipment, net (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
Dec. 31, 2015 |
|
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | $ 20,195 | $ 20,012 | |
Accumulated depreciation and amortization | (7,377) | (6,161) | |
Property and equipment, net | 12,818 | 13,851 | |
Depreciation and related amortization expense | 1,230 | $ 41 | |
Lasers Placed-In-Service [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 15,966 | 15,782 | |
Equipment, Computer Hardware and Software [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 1,244 | 1,219 | |
Furniture and Fixtures [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 2,054 | 2,080 | |
Leasehold Improvements [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | $ 931 | $ 931 |
Patents and Licensed Technologies, net (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
Dec. 31, 2015 |
|
Finite-Lived Intangible Assets [Line Items] | |||
Patents and licensed technologies, net | $ 7,003 | $ 7,247 | |
Estimated amortization expense [Abstract] | |||
Patents and licensed technologies, net | 7,003 | 7,247 | |
Core Technology [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Patents and licensed technologies, gross | 5,974 | 5,974 | |
Product Technology [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Patents and licensed technologies, gross | 2,000 | 2,000 | |
Patents and Licensed Technologies [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Patents and licensed technologies, gross | 7,974 | 7,974 | |
Accumulated amortization | (971) | (727) | |
Patents and licensed technologies, net | 7,003 | 7,247 | |
Amortization expense | 244 | $ 1 | |
Estimated amortization expense [Abstract] | |||
Remaining 2016 | 731 | ||
2017 | 975 | ||
2018 | 975 | ||
2019 | 975 | ||
2020 | 775 | ||
Thereafter | 2,572 | ||
Patents and licensed technologies, net | $ 7,003 | $ 7,247 |
Other Intangible Assets (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
Dec. 31, 2015 |
|
Finite-Lived Intangible Assets [Line Items] | |||
Other intangible assets, net | $ 7,770 | $ 7,980 | |
Estimated amortization expense [Abstract] | |||
Other intangible assets, net | 7,770 | 7,980 | |
Customer Relationships [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Other intangible assets, gross | 6,900 | 6,900 | |
Tradenames [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Other intangible assets, gross | 1,500 | 1,500 | |
Customer Relationships and Tradenames [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Other intangible assets, gross | 8,400 | 8,400 | |
Accumulated amortization | (630) | (420) | |
Other intangible assets, net | 7,770 | 7,980 | |
Amortization expense of other intangible assets | 210 | $ 0 | |
Estimated amortization expense [Abstract] | |||
Remaining 2016 | 630 | ||
2017 | 840 | ||
2018 | 840 | ||
2019 | 840 | ||
2020 | 840 | ||
Thereafter | 3,780 | ||
Other intangible assets, net | $ 7,770 | $ 7,980 |
Other Accrued Liabilities (Details) - USD ($) $ in Thousands |
Mar. 31, 2016 |
Dec. 31, 2015 |
---|---|---|
Other Accrued Liabilities [Abstract] | ||
Accrued warranty, current, see Note 1 | $ 155 | $ 168 |
Accrued compensation, including commissions and vacation | 921 | 1,336 |
Accrued sales and other taxes | 375 | 349 |
Accrued professional fees | 175 | 265 |
Other accrued liabilities | 13 | 43 |
Total other accrued liabilities | $ 1,639 | $ 2,161 |
Stockholders' Equity (Details) - $ / shares |
3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2016 |
Jan. 29, 2016 |
Dec. 31, 2015 |
Jul. 21, 2014 |
|
Class of Warrant or Right [Line Items] | ||||
Total Warrants (in shares) | 16,729,362 | |||
Exercise price (in dollars per share) | $ 1.06 | $ 1.13 | ||
Series A Warrants [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Exercise price (in dollars per share) | $ 2.45 | |||
Common Stock Warrant One [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Issue Date | Apr. 26, 2013 | |||
Expiration Date | Apr. 26, 2018 | |||
Total Warrants (in shares) | 69,321 | |||
Exercise price (in dollars per share) | $ 11.18 | |||
Common Stock Warrant Two [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Issue Date | Oct. 31, 2013 | |||
Expiration Date | Apr. 30, 2019 | |||
Total Warrants (in shares) | 685,715 | |||
Exercise price (in dollars per share) | $ 0.75 | |||
Common Stock Warrant Three [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Issue Date | Feb. 05, 2014 | |||
Expiration Date | Feb. 05, 2019 | |||
Total Warrants (in shares) | 1,329,731 | |||
Exercise price (in dollars per share) | $ 0.75 | |||
Common Stock Warrant Four [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Issue Date | Jul. 24, 2014 | |||
Expiration Date | Jul. 24, 2019 | |||
Total Warrants (in shares) | 6,198,832 | |||
Common Stock Warrant Four [Member] | Minimum [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Exercise price (in dollars per share) | $ 0.75 | |||
Common Stock Warrant Four [Member] | Maximum [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Exercise price (in dollars per share) | $ 2.45 | |||
Common Stock Warrant Five [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Issue Date | Jul. 24, 2014 | |||
Expiration Date | Jul. 24, 2016 | |||
Total Warrants (in shares) | 4,795,321 | |||
Exercise price (in dollars per share) | $ 0.75 | |||
Common Stock Warrant Six [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Issue Date | Jun. 22, 2015 | |||
Expiration Date | Jun. 22, 2020 | |||
Total Warrants (in shares) | 3,000,000 | |||
Exercise price (in dollars per share) | $ 0.75 | |||
Common Stock Warrant Seven [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Issue Date | Dec. 30, 2015 | |||
Expiration Date | Dec. 30, 2020 | |||
Total Warrants (in shares) | 650,442 | |||
Exercise price (in dollars per share) | $ 1.13 |
Stock-based compensation (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Number of Stock Options [Roll Forward] | ||
Stock-based compensation expense | $ 170 | $ 230 |
Unrecognized compensation expense | $ 488 | |
Unrecognized compensation expense, weighted average period | 1 year 1 month 24 days | |
Stock Options [Member] | ||
Number of Stock Options [Roll Forward] | ||
Stock based compensation options outstanding (in shares) | 2,614,600 | |
Stock based compensation weighted average exercise price (in dollars per share) | $ 1.51 | |
Stock based compensation vested (in shares) | 1,664,600 | |
Stock based compensation exercisable (in shares) | 1,664,600 |
Income taxes (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Income taxes [Abstract] | ||
Income tax expense change in deferred tax liability related to goodwill | $ 66 | $ 0 |
Business Segments and Geographic Data (Details) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016
USD ($)
Segment
|
Mar. 31, 2015
USD ($)
|
|
Segment Reporting Information [Line Items] | ||
Number of operating segments | Segment | 3 | |
Number of dermatology procedures segments | Segment | 2 | |
Results of Operations from Business Segments [Abstract] | ||
Revenues | $ 7,620 | $ 81 |
Cost of revenues | 3,422 | 711 |
Gross profit | $ 4,198 | $ (630) |
Gross profit % | 55.10% | (777.80%) |
Allocated operating expenses [Abstract] | ||
Engineering and product development | $ 525 | $ 239 |
Selling and marketing expenses | 3,710 | 1,027 |
Unallocated operating expenses | 2,101 | 1,736 |
Total operating expenses | 6,336 | 3,002 |
Income (loss) from operations | (2,138) | (3,632) |
Interest expense, net | (1,218) | (2,324) |
Change in fair value of warrant liability | 1,985 | (1,334) |
Other income (expense), net | 0 | 18 |
Income (loss) before income taxes | (1,371) | (7,272) |
Dermatology Recurring Procedures [Member] | ||
Results of Operations from Business Segments [Abstract] | ||
Revenues | 0 | |
Operating Segments [Member] | Dermatology Recurring Procedures [Member] | ||
Results of Operations from Business Segments [Abstract] | ||
Revenues | 5,528 | 0 |
Cost of revenues | 2,304 | 0 |
Gross profit | $ 3,224 | $ 0 |
Gross profit % | 58.30% | 0.00% |
Allocated operating expenses [Abstract] | ||
Engineering and product development | $ 311 | $ 0 |
Selling and marketing expenses | 3,510 | 0 |
Unallocated operating expenses | 0 | 0 |
Total operating expenses | 3,821 | 0 |
Income (loss) from operations | (597) | 0 |
Interest expense, net | 0 | 0 |
Change in fair value of warrant liability | 0 | 0 |
Other income (expense), net | 0 | 0 |
Income (loss) before income taxes | (597) | 0 |
Operating Segments [Member] | Dermatology Procedures Equipment [Member] | ||
Results of Operations from Business Segments [Abstract] | ||
Revenues | 1,990 | 0 |
Cost of revenues | 951 | 0 |
Gross profit | $ 1,039 | $ 0 |
Gross profit % | 52.20% | 0.00% |
Allocated operating expenses [Abstract] | ||
Engineering and product development | $ 62 | $ 0 |
Selling and marketing expenses | 108 | 0 |
Unallocated operating expenses | 0 | 0 |
Total operating expenses | 170 | 0 |
Income (loss) from operations | 869 | 0 |
Interest expense, net | 0 | 0 |
Change in fair value of warrant liability | 0 | 0 |
Other income (expense), net | 0 | 0 |
Income (loss) before income taxes | 869 | 0 |
Operating Segments [Member] | Dermatology Imaging [Member] | ||
Results of Operations from Business Segments [Abstract] | ||
Revenues | 102 | 81 |
Cost of revenues | 167 | 711 |
Gross profit | $ (65) | $ (630) |
Gross profit % | (63.70%) | (777.80%) |
Allocated operating expenses [Abstract] | ||
Engineering and product development | $ 152 | $ 239 |
Selling and marketing expenses | 92 | 1,027 |
Unallocated operating expenses | 0 | 0 |
Total operating expenses | 244 | 1,266 |
Income (loss) from operations | (309) | (1,896) |
Interest expense, net | 0 | |
Change in fair value of warrant liability | 0 | 0 |
Other income (expense), net | 0 | 0 |
Income (loss) before income taxes | (309) | (1,896) |
Reportable Geographical Components [Member] | Domestic [Member] | ||
Results of Operations from Business Segments [Abstract] | ||
Revenues | 5,622 | 38 |
Reportable Geographical Components [Member] | Foreign [Member] | ||
Results of Operations from Business Segments [Abstract] | ||
Revenues | $ 1,998 | $ 43 |
Significant Customer Concentration (Details) - Customer Concentration Risk [Member] $ in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2016
USD ($)
| |
Product Information [Line Items] | |
Revenues | $ 1,686 |
Accounts receivable | $ 443 |
Revenue [Member] | |
Product Information [Line Items] | |
Concentration risk percentage | 22.10% |
Accounts Receivable [Member] | |
Product Information [Line Items] | |
Concentration risk percentage | 13.60% |
Subsequent Events (Details) - Subsequent Event [Member] $ in Thousands |
Apr. 05, 2016
USD ($)
shares
|
---|---|
Subsequent Events [Line Items] | |
Debentures converted in shares of common stock, value | $ | $ 63 |
Debentures converted in shares of common stock (in shares) | shares | 84,411 |
:=!&IB%00@R8$A-3\\24F(:R8"%2$A$4H=;$D"DQ,S7/3$F@
M:4(KDF!3:QMP$P.GQ.34/#DE@:+E5TI)5"!MB%8Q=$K,3LVS4V(L @3&B; S
M"Z0<$",G8'+R6_D1,!.-L?PV"Y2OH34 ,7*"Q&L@E Q<%,.\W3#C#'I%3\
M]"R)K AN3!##'6#<&1YW@%$FA1(\?8FLR%6H?V/, \P\PS,/*,P,G\L0529"
MO((8\0#GFGSR=@1#ICB_**E(AGHFQD[ [#0\.X%@,= O6&-#O1(C)V!R&IZ<
MFR9[I. !,T2FBB+D)\9.P.PTGT"TG?*HQG*:,J2A3F+4DJ22 $B^R
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MJ7#L73J\);N\S@<>[^0#7A:#:.&W,*WL+3F@\S<;[Z9!=.!-9#<;2CK_?Y9
M0>/"\LZO37I2*7 XG#[(\DO+=U!+ P04 " "*8;!(*\AP!J(! "Q P
M&0 'AL+W=O U)()9BQ2U42W2I@N2<)3F@0'(A@=8/3Q.^]JC21G>%U Z\*Z4X(IOZ=
M@ KFND=M@MX[3E?7 1.6ARK(#5M#*V$&IH< 4E>JK-18%A )MF^]5AU!RZ;@U!Y0R35JQ-7UI0IW39?6^HYY0?T1BH(
M-J_WCI1&IEJC7IT$!(86HM+H6&_'4V:C](V9_;XJ<2@3R$H=MY/:N5\Q21@P
M&'N=N:.[CYT>0<&"LP6<=]N<' G7P!X >4&)EF9FGMQ12(*D 6QP-[0P?TWH
M9SX1*:>L_LC*R8F]BR4)LS3W0>N<:MU^I_D_?$GW_'BGU_BG&386YR>]_1T5.WKP;
M7D)]Q(BI,#$M3RE%8#AE5?QV3656Y*'U%*.FPM2T/*LV3?8_.321<3ETBKY-
MW:I7]T?5O];=D+SX3M\J'JXOWHIL+$EZEQ5U>='P^-NXSS;3;=]^L'N?5A
M]+>/[XN/CYR'?P%02P,$% @ BF&P2.R3FLY* @ :0@ !@ !X;"]W
M;W)K
@2I\V7$..T^=J' 4+Z&NXO2F1*
MP9R58GD#HNYRX@-!,6B%I(""N<5 $'>+\8&@&*RZ408HA%O,%,3=H+47!,5@
ME9*"4LEB#P56X"BL<)Z:0K$21T&-8XDKVZ<;4.II!RM>%%0OEGDHL*)#T[NR
MQ8H%S8 *ST(+0)QXVL&* 04NYKZ%&',Q(_=DRS#O,> 8SER%;S6"QM78;(0]
M^3)TVP",Q9W+_FH$V470EP_F&';/YH+Y=Q>P)GTHKTFMFPS!>0"
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M =$T]G'FGO(NWZP;3K-0B+V",)+
M4/-XMYX..;/H_8"!WL[[).).(;P$-H_!1L=S+++TJ=^GDIA3""^AS>/=+V;<
M>HE*'E&):5P#4R5'#SHD8D\AO$0FC_,V.J1[R)V,\6+Q+&'.(+R$)X\3-WHZ
M>IH\R$L$G+QXJHD6HW10]W"EJ2V].85$2GMNN$B8\P&U"DT&CW;Q34)3&ZM4
MFG%^)&9ZM-?/=%)$?N
0N,:AF\+?)58"C1*
K
MP7@Z@*K*?(E8E>.+99GZ]4QK$DA*9G]^M1D6]0Z<,-C^< F@?#8<1/1S ;;6<4REIJ\Z6I%+68J?756&)
ME!%,QYC(F P=2@27F-) 1:TH0*]0OYH,MDJE/H#8[_EZ)'8*4%2V1RR*#7-8\
M/SO8&/BW1"DPG]&5WV/1LR$*."I!ZY2&RE5IL7=L:A5*E'0&+C_=BZ+O'/9)
M>7,